Accessibilité
Animation
Accessibilité

Poster

HT-29 as a preclinical model for colorectal cancer

October 1, 2016

Treatment options for CRC are highly dependent on the stage of disease, but many patients receive cocktails of chemotherapies and in some cases radiation treatment along with chemotherapy. A number of preclinical xenograft models exist that allow pharmaceutical and biotech companies to investigate new treatment approaches for CRC. We have a number of CRC models (see Table 1) and HT-29 represents one of our most highly utilized lines. Figure 1 illustrates growth of the line following subcutaneous implant in nude mice. Most studies will stage within two weeks following implant and the tumor doubles roughly every six to seven days. We have used this model to test a number of chemotherapies, as shown in Figures 2-4.

Table 1: Colon Cell Lines with SpeciesFig. 1: Subcutaneous Growth of HT-29 Fragments Implanted Into nu/nu MiceFig. 2: Subcutaneous Growth of HT-29 Following Treatment with 5-FluorouracilFig. 3: Subcutaneous Growth of HT-29 Following Treatment with GemcitabineFig. 4: Subcutaneous Growth of HT-29 Following Treatment with Irinotecan

Fig. 4: Subcutaneous Growth of HT-29 Following Treatment with Irinotecan

In this model we have also evaluated the combination of radiation and gemcitabine (Figure 5) and illustrate the added benefit of the combination over either single agent treatment.

Fig. 4: Subcutaneous Growth of HT-29 Following Treatment with Irinotecan

Fig. 5: Subcutaneous Growth of HT-29 Following Combination Treatment with Localized Radiation and Gemcitabine

Contact us to discuss your next preclinical CRC study design.
 
 

References

Note: Please note that all animal care and use was conducted according to animal welfare regulations in an AAALAC-accredited facility with IACUC protocol review and approval.